MIST — Milestone Pharmaceuticals Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1408443 ·
Last close
$1.40
Market Cap
$174.30M
52W High
$2.34
52W Low
$1.00
ADV30
1,573,076
Next earnings
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 238,000 224,000 -23,663,000 -26,066,000 193,734,000 71,317,000 157,685,000
Dec 2025 1,546,000 -17,257,000 -17,409,000 113,561,000 73,046,000 71,792,000
Sep 2025 0 -11,829,000 -11,922,000 87,750,000 46,685,000 67,249,000
Jun 2025 0 -12,531,000 -12,966,000 47,417,000 42,499,000 65,162,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-49,041,000
Investing CF
$11,246,000
Financing CF
$85,527,000
CapEx
$-302,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.77
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-430,603,000
Inventory
$648,000
Receivables
$3,508,000
ST Investments
$32,914,000
EBIT TTM
$-59,220,000
Pretax Income TTM
$-63,058,000
Interest Exp TTM
$3,838,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,546,000
EBITDA
$-62,026,000
Free Cash Flow
$-28,903,250
Enterprise Value
$-19,352,768
Total Cash
$105,960,000
Total Debt
$58,377,000
Shares Out
124,497,980
Trailing EPS
$-0.64
Book Value
$0.34
ROE
-229.7%
ROA
-41.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,546,000 -62,140,000 -63,058,000 113,561,000 71,792,000 -49,041,000
Dec 2024 0 -42,102,000 -41,519,000 75,499,000 62,352,000 -28,848,000
Dec 2023 1,000,000 -61,098,000 -59,685,000 75,226,000 58,455,000 -46,424,000
Dec 2022 5,000,000 -59,642,000 -58,388,000 74,483,000 8,135,000 -52,469,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.04

Peers — same industry

TickerNameMarket CapLastDaily %
NGEN NERVGEN PHARMA CORP. $175.07M $2.13
IMUX IMMUNIC, INC. $176.67M $12.97
KRRO Korro Bio, Inc. $177.83M $12.33
ANTX AN2 Therapeutics, Inc. $170.36M $4.73
LFCR LIFECORE BIOMEDICAL, INC. \DE\ $180.05M $4.80

News headlines (Yahoo Finance, 1h cache)

Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer
2026-05-21 13:00 · Yahoo
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability
2026-05-15 10:49 · Yahoo
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-14 12:30 · Yahoo
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
2026-05-14 00:44 · Yahoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-05-13 23:00 · Yahoo
Why Milestone Pharmaceuticals Stock Wilted on Wednesday
2026-05-13 22:16 · Yahoo
Milestone Pharmaceuticals Q1 Earnings Call Highlights
2026-05-13 18:09 · Yahoo
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
2026-05-13 13:40 · Yahoo
Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST)
2026-05-13 13:34 · Yahoo
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
2026-05-13 12:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.